15 July 2025 in Applied Radiation and Isotopes
The ISOLPHARM project of the INFN aims to study the properties of the 111Ag β- emitter as a promising core for novel radiopharmaceuticals. 111Ag will be produced at the SPES facility of the Legnaro National Laboratories, with high specific activity and remarkable yields, exploiting the ISOL technique. This work presents Monte Carlo dosimetry calculations at cellular level to assess the therapeutic potential of 111Ag within the ADMIRAL project. Using the formalism introduced by the MIRD, S-values are calculated for a biological cell exposed to different scenarios of activity distributions of 111Ag. The results of dosimetry calculations performed with Geant4, MCNP6 and PHITS Monte Carlo codes are presented and discussed, showing a good mutual agreement and also with the MIRDcell values. These results will be used within the ISOLPHARM project for the planning of in-vitro experiments in 2D cell cultures and 3D tissue-mimicking scaffolds.
1 April 2026 in Journal of Instrumentation
Targeted Radionuclide Therapy (TRT) is a well-established technique for cancer treatment. In this approach, radionuclides are bound to specific drugs that selectively transport them to the tumor site. Within the ISOLPHARM project, a radiopharmaceutical for TRT based on the innovative radionuclide 111 Ag is currently under development. 111 Ag has a half-life of 7.45 days and decays by emitting both electrons and gamma-rays. The emission of gamma-rays, predominantly at an energy of 342 keV, enables the visualization of 111 Ag using a gamma camera. In this work, we describe a Monte Carlo simulation developed to optimize the design parameters of such an imaging device. The simulation is based on the Geant4 toolkit, which accurately models the interactions between particles and matter. The estimated spatial resolution and sensitivity of the system are approximately 4 mm and 19 cps/MBq, respectively. The simulated device is able to resolve lesions with a lesion-to-background activity ratio of 4:1 under in-vivo-like conditions. These results indicate that the proposed gamma camera can provide cost-effective imaging capabilities for preclinical radiopharmaceutical studies.
11 July 2025 in The European Physical Journal Special Topics
1 October 2026 in EJNMMI Physics
EFEleftherios Fysikopoulos
+2
This study aims to quantitatively evaluate the imaging performance of 111Ag in a preclinical planar SPECT system, with emphasis on scatter correction optim
12 May 2026 in SSRN Electronic Journal
JAJessica Carolina Delgado Alvarez
Jessica Carolina Delgado Alvarez
+4
Existing β-imaging devices typically have a field of view (FOV) of about 0.1 cm2, which is too small for imaging large cell cultures as a whole. To provide a complementary tool in radiopharmaceutical research, the Detector Using Maps for Beta-rays Observations (DUMBO) β-imaging device was developed, featuring lower spatial resolution but a larger FOV and non-invasive imaging capability.The prototype presented in this work consists of two ALICE PIxel DEtector (ALPIDE) chips, providing a total sensitive area of 3 cm x 3 cm. The sample can be positioned with three degrees of freedom, two of which are motorized using commercial stepper actuators. The performance was evaluated through Geant4 simulations and experimental measurements with the medical radionuclide 111Ag. Plastic and hydrogel phantoms were imaged to assess the device response to different sample types.The circular shape of the vials containing aqueous 111Ag solutions, as well as the structure of the plastic phantoms with 1-3 mm-wide channels, were clearly resolved. The simulated spatial resolution, which depends on the distance between source and detector, could reach values as good as 0.3 mm; however, sample preparation limited the experimentally achieved resolution. DUMBO demonstrated stable operation, straightforward sample handling, and clear detection capability for samples with activities of the order of 100 kBq.
3 August 2026 in Applied Radiation and Isotopes
Existing β-imaging devices with real-time image reconstruction typically have a field of view (FOV) of about 0.1cm2, which is too small for imaging large cell cultures as a whole. To provide a complementary tool in radiopharmaceutical research, the Detector Using Maps for Beta-rays Observations (DUMBO) β-imaging device was developed, featuring lower spatial resolution but a larger FOV and non-invasive imaging capability. The prototype presented in this work consists of two ALICE PIxel DEtector (ALPIDE) chips, providing a total sensitive area of 3cm × 3cm. The sample can be positioned with three degrees of freedom, two of which are motorized using commercial stepper actuators. The performance was evaluated through Geant4 simulations and experimental measurements with the medical radionuclide 111Ag. Plastic and hydrogel phantoms were imaged to assess the device response to different sample types. The circular shape of the vials containing aqueous 111Ag solutions, as well as the structure of the plastic phantoms with 1-3 mm-wide channels, were clearly resolved. The simulated spatial resolution, which depends on the distance between source and detector, could reach values as good as 0.3mm; however, sample preparation limited the experimentally achieved resolution. DUMBO demonstrated stable operation, straightforward sample handling, and clear detection capability for samples with activities of the order of 100kBq.